% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Solomonidou:274211,
      author       = {N. Solomonidou and D. Germanou and I. Strouthos and E.
                      Karagiannis and A. Farolfi and S. A. Koerber$^*$ and J.
                      Debus$^*$ and J. C. Peeken$^*$ and M. E. Vogel$^*$ and A.
                      Vrachimis and S. K. B. Spohn$^*$ and M. Shelan and D.
                      Aebersold and A.-L. Grosu$^*$ and F. Ceci and S. G. C.
                      Kroeze and M. Guckenberger and S. Fanti and C. Belka and G.
                      Hruby and S. Scharl and T. Wiegel and P. Bartenstein and C.
                      Henkenberens and L. Emmett and N. S. Schmidt-Hegemann and K.
                      Ferentinos and C. Zamboglou$^*$},
      title        = {{PSMA}-{PET}/{CT}-guided salvage radiotherapy in recurrent
                      or persistent prostate cancer and {PSA} $\<$ 0.2 ng/ml.},
      journal      = {European journal of nuclear medicine and molecular imaging},
      volume       = {50},
      number       = {8},
      issn         = {1619-7070},
      address      = {Heidelberg [u.a.]},
      publisher    = {Springer-Verl.},
      reportid     = {DKFZ-2023-00497},
      pages        = {2529-2536},
      year         = {2023},
      note         = {2023 Jul;50(8):2529-2536},
      abstract     = {The purpose of this retrospective, multicenter study was to
                      assess efficacy of PSMA-PET/CT-guided salvage radiotherapy
                      (sRT) in patients with recurrent or persistent PSA after
                      primary surgery and PSA levels < 0.2 ng/ml.The study
                      included patients from a pooled cohort (n = 1223) of 11
                      centers from 6 countries. Patients with PSA levels > 0.2
                      ng/ml prior to sRT or without sRT to the prostatic fossa
                      were excluded. The primary study endpoint was biochemical
                      recurrence-free survival (BRFS) and BR was defined as PSA
                      nadir after sRT + 0.2 ng/ml. Cox regression analysis was
                      performed to assess the impact of clinical parameters on
                      BRFS. Recurrence patterns after sRT were analyzed.The final
                      cohort consisted of 273 patients; 78/273 $(28.6\%)$ and
                      48/273 $(17.6\%)$ patients had local or nodal recurrence on
                      PET/CT. The most frequently applied sRT dose to the
                      prostatic fossa was 66-70 Gy (n = 143/273, $52.4\%).$ SRT to
                      pelvic lymphatics was delivered in 87/273 $(31.9\%)$
                      patients and androgen deprivation therapy was given to
                      36/273 $(13.2\%)$ patients. After a median follow-up time of
                      31.1 months (IQR: 20-44), 60/273 $(22\%)$ patients had
                      biochemical recurrence. The 2- and 3-year BRFS was $90.1\%$
                      and $79.2\%,$ respectively. The presence of seminal vesicle
                      invasion in surgery (p = 0.019) and local recurrences in
                      PET/CT (p = 0.039) had a significant impact on BR in
                      multivariate analysis. In 16 patients, information on
                      recurrence patterns on PSMA-PET/CT after sRT was available
                      and one had recurrent disease inside the RT field.This
                      multicenter analysis suggests that implementation of
                      PSMA-PET/CT imaging for sRT guidance might be of benefit for
                      patients with very low PSA levels after surgery due to
                      promising BRFS rates and a low number of relapses within the
                      sRT field.},
      keywords     = {PSMA-PET (Other) / Prostate cancer (Other) /
                      Prostate-specific antigen (Other) / Salvage radiotherapy
                      (Other)},
      cin          = {E050 / MU01 / FR01},
      ddc          = {610},
      cid          = {I:(DE-He78)E050-20160331 / I:(DE-He78)MU01-20160331 /
                      I:(DE-He78)FR01-20160331},
      pnm          = {315 - Bildgebung und Radioonkologie (POF4-315)},
      pid          = {G:(DE-HGF)POF4-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36905411},
      doi          = {10.1007/s00259-023-06185-5},
      url          = {https://inrepo02.dkfz.de/record/274211},
}